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Abstract
Development and improvement of quality control tests for live attenuated vaccines are a high 
priority because of safety concerns. Live attenuated influenza vaccine (LAIV) viruses are 6:2 
reassortants containing the hemagglutinin (HA) and neuraminidase (NA) gene segments from 
circulating influenza viruses to induce protective immune responses, and the six internal gene 
segments from a cold-adapted Master Donor Virus (MDV). LAIV candidate viruses for the 2012–
2013 seasons, A/Victoria/361/2011-CDC-LV1 (LV1) and B/Texas/06/2011-CDC-LV2B (LV2B), 
were created by classical reassortment of A/Victoria/361/2011 and MDV-A A/Leningrad/
134/17/57 (H2N2) or B/Texas/06/2011 and MDV-B B/USSR/60/69. In an attempt to provide 
better identity and stability testing for quality control of LV1 and LV2B, sensitive real-time RT-
PCR assays (rRT-PCR) were developed to detect the presence of undesired gene segments (HA 
and NA from MDV and the six internal genes from the seasonal influenza viruses). The sensitivity 
of rRT-PCR assays designed for each gene segment ranged from 0.08 to 0.8 EID50 (50% of Egg 
Infectious Dose) per reaction for the detection of undesired genes in LV1 and from 0.1 to 1 EID50 
per reaction for the detection of undesired genes in LV2B. No undesired genes were detected 
either before or after five passages of LV1 or LV2B in eggs. The complete genome sequencing of 
LV1 and LV2B confirmed the results of rRT-PCR, demonstrating the utility of the new rRT-PCR 
assays to provide the evidence for the homogeneity of the prepared vaccine candidate.
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Influenza A and B viruses are responsible for annual epidemics and significant morbidity 
and mortality in the human population worldwide (Thompson et al., 2003). Vaccination is 
an important intervention for preventing influenza and reducing the public health impact of 
epidemics and pandemics (Ambrose et al., 2011; Osterholm et al., 2012). Global Pandemic 
Influenza Action Plan to increase vaccine supply was initiated by the World Health 
Organization (WHO) in November of 2006 and refined further in 2011. One of the 
objectives was to expand vaccine production capacity by building new production facilities 
to strengthen pandemic influenza preparedness and response. The Institute of Experimental 
Medicine (IEM, St Petersburg, Russia) contributed to the Global Pandemic Influenza Action 
Plan by establishing an agreement with the WHO to supply Russian LAIV reassortant 
viruses to manufacturers in developing countries who could then provide influenza vaccines 
to the public (Rudenko et al., 2011). The increased international demand of Russian LAIV 
reassortant viruses prompted the WHO and IEM to establish a back-up facility at the Centers 
of Disease Control and Prevention (CDC), Influenza Division to prepare and incorporate 
quality assessment of LAIV reassortants for international use.
Seasonal influenza vaccines contain two types A viruses (H1N1 and H3N2) and one type B 
virus to elicit immunity to currently circulating influenza viruses (Fiore et al., 2009). Two 
major types of influenza vaccines are licensed for human use: trivalent inactivated influenza 
vaccine (TIV) and LAIV. LAIV is administered intranasally which mimics natural infection 
and protects against the disease caused by the influenza viruses (Aleksandrova, 1977; Cox et 
al., 2004; Maassab and DeBorde, 1985).
The development of LAIV became possible with the generation of cold-adapted (ca) type A 
and B Master Donor Viruses (MDVs). Both MDVs have three phenotypes: (1) allow 
efficient viral replication at 25 °C and 33 °C (ca), (2) restrict replication at temperatures 
above 39 °C (temperature-sensitive, ts), and (3) do not cause classical influenza-like illness 
and are restricted in replication in the lower respiratory tract (attenuated, att) (Maassab and 
Bryant, 1999; Murphy and Coelingh, 2002; Rudenko et al., 1996). LAIV are 6:2 reassortant 
viruses that contain the HA and NA gene segments from circulating influenza viruses to 
induce protective immune responses and the six internal gene segments (PB1, PB2, PA, NP, 
M, and NS) from MDVs provide ca, ts and att phenotypes of LAIV. In addition to 
conferring the ts and ca phenotypes, MDV also allows the reassortant viruses to replicate 
efficiently in embryonated chicken eggs as all licensed LAIVs are currently produced in 
embryonated chicken eggs.
Due to constant antigenic drift of circulating influenza viruses, the individual strains of the 
vaccine are updated annually based on WHO recommendations. A/Victoria/361/2011 
(H3N2)-like and B/Wisconsin/1/2010-like viruses were recommended by the WHO for 
vaccine use in the 2012–2013 influenza season. Classical reassortment methods were used to 
produce vaccine candidate viruses by co-infection of A/Victoria/361/2011 and MDV-A A/
Leningrad/134/17/57 (H2N2) or B/Texas/06/2011 and MDV-B B/USSR/60/69 followed by 
genotyping a number of virus progeny for selection of the 6:2 reassortants. To enhance the 
genetic homogeneity, virus cloning by serial limiting dilution in eggs was performed. 
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Sensitive control of reassortant genetic composition is necessary to provide evidence that 
there are no contaminating wild type (wt) viruses present that may replicate efficiently in 
patients and cause illness and to assure that the vaccine strain does not contain HA and NA 
from MDVs. A challenge for the limiting dilution cloning in eggs method is the possibility 
of obtaining an impure vaccine candidate. According to WHO guidelines for generation and 
characterization of LAIV candidates, biological materials for vaccine production, such as 
seed viruses and intermediates should be fully and up-to-date characterized to assure the 
quality, safety, and efficacy of LAIV for intranasal administration (WHO, 2009). The safety 
concerns necessitate accurate, sensitive and reliable methods to characterize the quality of 
LAIV seed candidates generated by classical reassortment. The current techniques for 
identity/homogeneity testing of reassortant influenza vaccines are the ones used for 
genotyping – analysis of restriction fragment length polymorphism of viral genes amplified 
by RT-PCR (Fulvini et al., 2011; Klimov and Cox, 1995; Sakamoto et al., 1996), multiplex 
RT-PCR (Ha et al., 2006; Lee et al., 2010) and Sanger sequencing – all are based on 
conventional RT-PCR method. In an attempt to provide better quality control of LAIV 
candidate viruses and to ensure the uniform composition of the A/Victoria/
361/2011(H3N2)-CDC-LV1 (LV1) and B/Texas/06/2011-CDC-LV2B (LV2B) reassortants 
(designated as Master Virus Seed, MVS), real-time RT-PCR assays were developed to 
confirm the lack of any genetic material of undesired origin in the reassortant viruses.
2. Materials and methods
2.1. Viruses
Egg adapted wt influenza virus strains A/Victoria/361/2011 (passage history in eggs – 
E3/E2, where E#/means number of egg passages in submission laboratory and/E# means 
number of egg passages in CDC) and B/Texas/06/2011 (E4) were obtained from CDC 
repository. The clones of cold-adapted MDV-A A/Leningrad/134/17/57(H2N2), and MDV-
B B/USSR/60/69 were obtained at the IEM, St Petersburg, Russia. MDV stocks were 
prepared in 10-day-old SPF eggs (Charles River Laboratories Inc., Wilmington, MA) and 
stored at −80 °C. Infectious titer of wt and MDVs were measured by 50% egg infectious 
dose per milliliter (EID50/ml) as previously described (Huprikar and Rabinowitz, 1980). 
Briefly, 10-fold serial dilutions of allantoic fluid were made in PBS (137 mM NaCl, 10 mM 
phosphate, 2.7 mM KCl, pH of 7.4) and 0.2 ml of each dilution was inoculated into 10-day-
old SPF eggs. Five eggs were infected with each virus dilution and incubated at 32 °C for 48 
h for influenza A virus and 72 h for influenza B virus. Harvested allantoic fluids were tested 
for HA activity using 0.5% turkey red blood cells (tRBC). The virus titer was calculated 
using Reed and Muench method (Reed and Muench, 1938).
2.2. Reassortment of ca donor and wt influenza viruses
Reassortant influenza viruses that possess the internal genes of MDV-A or MDV-B and the 
surface genes of A/Victoria/361/2011 or B/Texas/06/2011, respectively, were prepared 
according to a method developed by the IEM, St Petersburg, Russia (Aleksandrova, 1977; 
Wareing et al., 2002). Briefly, equal doses (~106 EID50) of the donor and wt strains were 
inoculated into 10-day-old SPF eggs and incubated at 32 °C for 2 (influenza A) or 3 
(influenza B) days. HA-positive allantoic fluids were combined and diluted 1:10 with 
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antiserum prepared against the MDV-A in ferrets and against MDV-B in rabbits (provided 
by IEM, St Petersburg, Russia, through WHO). The virus–serum mixtures were incubated 
overnight at 4 °C and then passaged once in SPF eggs at 25 °C for 6 days. If needed, a blind 
passage at 32 °C was performed. All HA-positive allantoic fluids were combined. A second 
selective passage of HA-positive allantoic fluids was then carried out in the presence of 
antiserum at 25 °C followed by cloning procedures (Wareing et al., 2002).
2.3. Isolation of viral RNA
RNA was isolated from influenza virus-containing allantoic fluids and purified on the 
MagnaPure LC (Roche, San Francisco, CA) using the MagNA Pure Total Nucleic Acid Kit 
(Roche, San Francisco, CA) following the manufacturer’s instructions. Clarified allantoic 
fluid of infected eggs (200 μL) was used for RNA isolation. RNAs were eluted in a final 
volume of 50 μL of RNase-free water.
2.4. Genotyping of reassortants
Genome composition of reassortant influenza viruses was assessed by standard 
hemagglutination inhibition assay (for HA) and pyrosequencing analysis (for NA and the 
other six genes) (Deng et al., 2011).
2.5. Real time RT-PCR (rRT-PCR)
Strain-specific and segment-specific primers/probe sets for rRT-PCR were designed for 
genes of A/Leningrad/134/17/57 (Table 1), A/Victoria/361/2011 (Table 2), B/Texas/06/2011 
(Table 3) and B/USSR/60/69 using GenScript Real-time PCR TaqMan Primer Design 
(GenScript, Piscataway, NJ) and PrimerExpress 3.0 Software (Applied Biosystems, Foster 
City, CA). Primers/probe sets for B/USSR/60/69 are not provided for the reasons of 
intellectual property rights associated with this master donor virus. Primers/probe sets for 
universal detection of H3 and H2 subtypes, and specific detection of PB1 gene of LAIV-A 
(FluMist) were provided by Diagnostic Development Team, VSDB, Influenza Division, 
CDC (primer and probes available upon request). The rRT-PCR was performed using 
SuperScript® III Platinum®One-Step quantitative RT-PCR Kit (Invitrogen, Carlsbad, CA) 
on Mx3000P thermal cycler (Agilent Technologies, Santa Clara, CA). The reaction was 
conducted in a total volume of 25 μl containing 0.8 μM of each primer and 0.2 μM of probe 
and 5 μl of viral RNA. Reaction conditions were as follows: one cycle of 50 °C for 15 min, 
followed by 2 min at 95 °C, and 45 cycles of 15 s at 95 °C and 1 min at 60 °C. The data 
were analyzed using MxPro QPCR Software.
RNAs were extracted from viruses in allantoic fluid with known infectious titer. Serial 10-
fold dilutions were prepared in RNase-free water. Standard curves were generated with 
duplicate samples over a template dilution range of 6 logs by using obtained cycle threshold 
(Ct) with a difference between replicates of < 0.5 Ct values. The resulting Ct values for each 
dilution were plotted versus virus EID50. The linear regression analysis was applied to 
determine the slopes. By using obtained Ct values the amplification efficiencies were 
calculated as E = (10(−1/slope) − 1) × 100.
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2.6. Reassortant virus passaged in eggs for stability analysis
Reassortant MVS (Master Virus Seed) stocks were tested for genome stability and the 
absence of contamination by wt viruses after five consecutive passages in SPF eggs (An et 
al., 2009). Briefly, vaccine candidate viruses were diluted with PBS to the final virus 
concentration of 5 × 105 EID50/ml and three 10-day-old SPF eggs were inoculated with 0.2 
ml of the diluted virus. The eggs were incubated for 48 h (influenza A) or 72 h (influenza B) 
at 32 °C, then were chilled (4 °C 3 h to overnight) and allantoic fluids from each egg were 
harvested and pooled together. The virus titer was estimated in HA assay using 0.5% tRBC. 
The average ratio between number of influenza virus particles and HA units has been 
reported to be 107 particles/HA per mL with the deviation about 8%, depending of virus 
strains and type of RBC (Desselberger, 1975; Donald and Isaacs, 1954; Isaacs, 1957; Tyrrell 
and Valentine, 1957). Thus, allantoic fluid with 500 HA titer is estimated to contain about 5 
× 109 virus particles per mL. Approximately ten virus particles correspond to one EID50/mL 
(Donald and Isaacs, 1954). The infectivity of allantoic fluid with 500 HA unit would 
correspond to about 5 × 108 EID50/mL. To keep the same level of multiplicity of infection in 
the following passages, the allantoic fluid with HA titer of 500 were diluted 1000 times with 
PBS to final 5 × 105 EID50/mL and SPF eggs were inoculated with 0.2 mL/egg. After the 
5th passage in eggs, allantoic fluids were collected and clarified by low speed centrifugation 
at 300 × g for 10 min and used for further analysis.
2.7. Genomic sequence analysis
The complete viral cDNAs for each segment (PB2, PB1, PA, HA, NP, NA, M and NS) of 
the cloned viruses were synthesized from purified viral RNA using AccessQuick RT-PCR 
system (Promega, Madison, USA). Viral genome fragments (eight for PB2, PB1 and PA, six 
for HA, five for NP and NA, and three for M and NS) were amplified using overlapping 
M13 tagged gene segment specific primers. RT-PCR products were resolved by the 2% E-
Gel 96 agarose electrophoresis system (Invitrogen, Carlsbad, CA) and were purified by 
ExoSAP-IT system (Affymetrix/USB, Cleveland, OH). Sanger sequencing of the cDNA was 
performed with the M13 primers using the BigDye Terminator v3.1 Cycle Sequencing kit 
(Applied Biosystems, Foster City, CA). The sequencing extension products were purified 
using the Agencourt CleanSEQ (Agencourt/Beckman Coulter, Brea, CA) and analyzed 
using an ABI 3730xl DNA Analyzer (Applied Biosystems, Foster City, CA) and 3730 Data 
Collection v3.0 software (Applied Biosystems, Foster City, CA). Trace files were assembled 
in Sequencer (Gene Codes Corporation, Ann Arbor, MI). BioEdit Sequence Alignment 
Editor (Thomas Hall/Ibis Biosciences, Carlsbad, CA) software was used to align consensus 
sequences of gene segments with the corresponding sequences of MDV-A and wt A/
Victoria/361/2011 or MDV-B and wt B/Texas/06/2011 viruses.
3. Results
3.1. Specificity and sensitivity of the designed rRT-PCR assays
For each wt-MDV pair used to create reassortants, primers/probe sets for rRT-PCR were 
designed to match the genome of only one of the virus strain of the pair (Tables 1–3). To 
verify the specificity of the primer sets, viral RNAs were isolated and purified from 107 
EID50/mL wt and MDV viruses, and used for rRT-PCR reaction. Each virus RNA (MDV 
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and wt) was tested by rRT-PCR with all primers/probe sets designed for that pair. These 
primers amplified only a specific product. None of the cross-templates resulted in a positive 
signal, confirming that the designed primers/probe sets were strain and segment specific. 
The examples of test amplification curves are shown in Fig. 1.
The sensitivity was determined for each rRT-PCR primers/probe set for the detection of the 
undesired genetic materials in the prepared clonal MVS stocks. The amplification efficiency 
between 90% and 110% means doubling of the amplicon at each cycle. This corresponds to 
a slope of standard curve −3.1 to −3.6. Standard curves obtained showed that designed 
assays had amplification efficiency in 90–110% range and R2 values were 0.98–0.99 (Fig. 
2).
The limit of detection was determined as the lowest concentration at which positive signal 
was obtained (Table 4). The limit of detection of rRT-PCR using primer/probe sets for A/
Victoria/361/2011 PA and PB2 was at 0.08 EID50 per reaction, followed by 0.8 EID50 for 
PB1, NP, M and NS, and 1.3 EID50 for MDV-A HA and NA. In the case of influenza B 
strains, B/Texas/06/2011 PB2, PB1, PA, and NS primer/probe sets were most sensitive at 
0.1 EID50/reaction followed by 1 EID50 for NP and M. LoD for MDV-B HA NA genes 
were 1 EID50/per reaction.
3.2. Genetic homogeneity test
Using the highly specific and sensitive rRT-PCR protocol as described above, the genetic 
homogeneity of reassortant viruses, LV1 and LV2B, were analyzed using RNA 
corresponding to 105 EID50/per reaction. MDV and wt viruses were also tested as controls. 
For both reassortants, the positive signals were detected only with primers/probe specific for 
internal genes of MDV and HA and NA genes of wt (A/Victoria/361/2011 for LV1 and B/
Texas/06/2011 for LV2B). No undesired genes were detected in the reassortant viruses with 
a high sensitivity level of detection (Table 5). The data showed that the A/Victoria/
361/2011(H3N2)-CDC-LV1 reassortant does not contain genetic material from PB2, PB1, 
PA, NP, M and NS genes of A/Victoria/361/2011 or HA and NA genes of originating from 
A/Leningrad/134/17/57. Similarly, the B/Texas/06/2011-CDC-LV2B reassortant does not 
contain any genetic material of B/Texas/06/2011 genes PB2, PB1, PA, NP, M, NS or HA 
and NA genes of B/USSR/60/69 origin, confirming of genetic homogeneity of the 
reassortant viruses.
The genome sequence analysis of LV1 and LV2B was completed by alignment of the six 
internal protein gene segments (PB2, PB1, PA, NP, M, and NS) with those of corresponding 
MDVs and the two surface antigen segments, HA and NA, with the corresponding RNA 
segments of the wt A/Victoria/361/2011 or B/Texas/06/2011. The rRT-PCR analysis was 
consistent with the full genome sequence analysis. The alignment of sequences for the six 
internal gene segments of LV1 detected no nucleotide changes. LV2B contained only one 
nucleotide change in the NP gene segment (T66C) that did not result in amino acid 
substitution. No other mutations in the remaining internal gene segments were identified. 
The HA and NA sequences of LV1 were identical to one of the egg adapted A/Victoria/
361/2011. The HA sequence of wt B/Texas/06/2011, E4 isolate, which was used for 
reassortment, was shown to have a mix at position 596 (A or C) compared to E3 isolate 
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which had 596A. The A596C change led to amino acid Q200P substitution, since this 
mutation appeared during passage of virus in eggs it constitutes an egg adapted change. 
LV2B HA gene had 596C indicating the presence of 200P. NA sequence was identical to the 
NA of wt virus.
3.3. Genetic stability test
To test the genetic stability, LAIV reassortant viruses, LV1 and LV2B were subjected to 
five passages in SPF eggs. The infectious titers of original LAIV reassortants were 109.3 and 
109.2 EID50/mL for LV1 and LV2B, respectively. Passages were done with 0.2 ml of a 10−3 
dilution of the virus which corresponds to approximately 105 EID50 of virus per egg. RNA 
purified from five time passaged viruses was subjected to rRT-PCR procedure to confirm 
the homogeneity of the virus. No signal was detected in the reactions with RNA from the 
passaged LV1 reassortant when Victoria PB2, PB1, PA, NP, M, NS, or MDV-A NA and HA 
primers/probe sets were used. Similarly, no signal was detected with LV2B RNA when 
Texas internal genes and MDV-B NA and HA primers/probe sets were used, confirming 
again that the obtained reassortants were genetically homogeneous and did not contained 
genetic material of undesired origin.
The LV1 and LV2B viruses passaged five times in eggs were also characterized by complete 
full genome sequencing. Sequence alignments of all gene segments of the passaged virus 
with corresponding sequences of the original LV1 or LV2B did not reveal any nucleotide 
differences between them, indicating the genetic stability of the LAIV reassortant genome.
4. Discussion
Tests to characterize the quality of live attenuated influenza vaccine viruses are being 
continuously developed and improved (Buonagurio et al., 2006; Yeolekar and Dhere, 2012). 
The WHO recently updated recommendations to provide vaccine manufacturers and 
national regulatory authorities with guidance in developing specific processes to assure the 
quality, safety, and efficacy of live attenuated influenza vaccines for intranasal 
administration (WHO, 2009). The testing guidelines for the infectivity (potency), identity, 
sterility and stability of vaccine were outlined in this document. According to the guideline, 
LAIV candidates should be characterized by an identity test during their preparation. The 
identity test should include appropriate methods to identify the HA and NA antigens and to 
obtain phenotypic and genetic information for the vaccine viruses (WHO, 2009). Genotypic 
characterization of a vaccine virus should include its complete sequence, and may include 
analysis of viral subpopulations and its genetic stability. The stability of the genotype and 
phenotype should also be demonstrated following viral passages beyond the level used in 
vaccine production (WHO, 2009). In this study, the real-time RT-PCR assays were 
developed for both type A and type B LAIV reassortants, and its sensitivity was tested in an 
attempt to provide better identity and stability testing for quality control of LAIV candidate 
viruses.
LAIV candidates for the 2012–2013 seasons, A/Victoria/361/2011-CDC-LV1 (LV1) and B/
Texas/06/2011-CDC-LV2B (LV2B) were created by the classical viral reassortment 
method. The genetic identity of vaccine candidate viruses was demonstrated by 
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pyrosequencing assay at the stage of vaccine candidate selection. The pyrosequencing 
approach as well as most of the other current techniques used for genotyping and screening 
of reassortant influenza viruses are based on conventional RT-PCR technique (Fulvini et al., 
2011; Ha et al., 2006; Kiseleva et al., 2011; Klimov and Cox, 1995; Lee et al., 2010; 
Sakamoto et al., 1996). The sensitivity of the RT-PCR was shown to be at least log10 lower 
compared to rRT-PCR technique in a number of reports (Chen et al., 2007; Emery et al., 
2004; Kaida et al., 2008; Rodrigues et al., 2011; Zhao et al., 2007). For example, the rRT-
PCR H5 gene assay designed for avian influenza reproducibly determined lowest amount of 
viral RNA corresponding 0.05 EID50 per reaction in contrast to detection limit of 3 EID50 in 
cnRT-PCR (Chen et al., 2007). Real time RT-PCR is currently recognized as the most 
sensitive and reliable technique for detection and identification of viral subpopulations in 
diagnostics. The highest sensitivity of rRT-PCR assays was demonstrated for the detection 
of influenza viruses of different origin and composition (Chen et al., 2007; Monne et al., 
2008; Nakauchi et al., 2011; Shu et al., 2011). The rRT-PCR assays reported for detection of 
subtype H5, H7, and H9 avian influenza viruses had sensitivity from 0.5 to 2.74 EID50/per 
reaction (Monne et al., 2008). The sensitivity of rRT-PCR assays developed in the present 
study was shown to range from 0.08 to 0.8 EID50 per reaction for the detection of undesired 
genes in LV1 and from 0.1 to 1 EID50/reaction for the detection of undesired genes in 
LV2B. Therefore, primer/probe sets used in the current study allowed genome detection as 
sensitive as those reported in other studies using rRT-PCR assays (Chen et al., 2007; Monne 
et al., 2008; Spackman et al., 2002; Wise et al., 2004). However, it should be noted that 
although the designed primers and probes for MDVs are expected to work for the next 
MDV–wt reassortment pairs, the primer and probes sequences for next selected for vaccine 
wt virus must be checked and updated regularly and the limit of detection should be 
identified using that specific wt RNA.
During the vaccine manufacturing process, MVS undergoes three to four additional passages 
before blending the monovalent pool to formulate LAIV (Buonagurio et al., 2006; WHO, 
2009). It is important to determine that no other genetic material is present in the MVS 
which could be assured by rRT-PCR homogeneity test. In the present study, the 
homogeneity of the original and passaged LV1 and LV2B viruses were analyzed by rRT-
PCR and genetic stability was confirmed by complete sequencing of all gene segments. The 
rRT-PCR data demonstrate that neither of the reassortant viruses contained genetic material 
from internal genes of wt parental viruses or HA and NA genes of MDV origin with a high 
sensitivity levels of assays (Table 5). The rRT-PCR results were confirmed by sequencing 
analysis. No nucleotide change was found in sequences of passaged five times LV1 or 
LV2B viruses indicating the high level of genetic stability. The data obtained in the present 
study are in good agreement with the previous study on genetic stability of FluMist/CAIV-T 
vaccine, which demonstrated a remarkable sequence identity for all vaccine intermediates 
throughout the manufacturing process (Buonagurio et al., 2006)
The fact that no undesired genes were detected after five passages of MVS by rRT-PCR 
proves that the developed rRT-PCR assays were adequate and sufficient to provide the 
evidence for the homogeneity of the prepared vaccine candidate. In conclusion, both rRT-
PCR and sequencing results provide conclusive safety controls for further manufacturing 
processing of MVS. The real-time RT-PCR assays developed in the present study are in 
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compliance with WHO recommendations to provide further quality control steps to ensure 
safe use of LAIV.
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Fluorescence amplification curves of rRT-PCR assays using RNAs purified from A/
Victoria/361/11 (Vic) or MDV-A (Len) (A and B) or B/Texas/06/2011 (Tex) or MDV-B 
(USSR) (C and D). Primer/probe sets for Vic PA (A), Len PA (B), Tex PB2 (C) or USSR 
PB2 (D) were used for the reactions.
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Standard curves demonstrating the limit of detection studies of rRT-PCR assays for PA gene 
of A/Victoria/361/11 (A), PA gene of MDV-A (B), PB2 gene of B/Texas/06/2011 (C) and 
PB2 gene of MDV-B (D). Ten-fold dilutions of viral RNA were plotted against the threshold 
cycle. The coefficient of determination (R2 ) and the equation of the regression curve (y) 
calculated are shown.
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Table 1
Primers and probes used for real-time RT-PCR amplification of A/Leningrad/134/17/57 (H2N2).
Primers/probesa Gene Nucleotides Sequence 5′→3′
NSLenF150 NS 150–169 CGGTCTGAACATCGAAACAG
NSLenR230 NS 210–230 AGTGCCTCATCGGATTCTTCC
NSLenP197r NS 173–197 FAM-TCCACTATCTGCTTTCCAACACGGG-BHQ1
MLenF427 M 427–445 GCCTTGGGCCTGGTATGTG
MLenR488 M 465–488 CTATGAGACCTATGCTGGGAGTCA
MlenP447 M 447–463 FAM-AACCTGTGAACAGATTG-BHQ1
NALenF946 NA 946–965 TATGTGTGCTCAGGGCTTGT
NALenR1041 NA 1021–1041 TGGATTCCCTCTCTCATTGTT
NALenP967 NA 967–986 FAM-GGCGACACACCCAGGAACGA-BHQ1
NPLenF743 NP 743–764 CAGGAAATGCTGAGATCGAAGA
NPLenR813 NP 789–813 AGCAACTGACCCTCTCAATATGAGT
NPLenP769 NP 769–785 FAM-ATCTTTCTGGCACGGTC-BHQ1
PALenF1222 PA 1222–1242 CAGAATGAGTTCAACAAGGCA
PALenR1301r PA 1282–1301 GGAGCCACATCTTCTCCAAT
PALenP1243 PA 1243–1265 FAM-TGCGAGCTGACCGATTCAATCTG-BHQ1
PB2LenF976 PB2 976–995 GGCGGGTTCACATTTAAGAG
PB2LenR1053 PB2 1034–1053 TGTTTGAAGATTGCCCGTAA
PB2LenP1026r PB2 1001–1026 FAM-TTCCTCTCTCTTGACTGATGATCCGC-BHQ1
a
F and R in the primer name indicate forward and reverse direction, respectively. P indicates probe, and r indicates probe in reverse direction.
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Table 2
Primers and probes used for real-time RT-PCR amplification of A/Victoria/361/2011 (H3N2).
Primers/probesa Gene Nucleotides Sequence 5′→3′
NSVicF149 NS 149–169 TCGGTCTAGACATCAAAGCAG
NSVicR234 NS 211–234 TTTAAGTGCCTCATCAGATTCTTC
NSVicP170 NS 170–193 FAM-CCACCCATGTTGGAAAGCAAATTG-BHQ1
MVicF809 M 809–833 TGGATTCTTGATCGTCTTTTTTTCA
MVicR875 M 854–874 GCCTCTTTTAAGGCCGTGTTT
MVicP834 M 835–851 FAM-ATGCGTCTATCGACTCT-BHQ1
NAVicF1106 NA 1106–1125 CGTCACGCTTAGGGTATGAA
NAVicR1215 NA 1197–1216 AACCGGACCTATCACCTCTG
NAVicP1136 NA 1136–1158 FAM-TCATTGAAGGCTGGTCCAACCCT-BHQ1
NPVicF838 NP 838–858 GCGTATGGACCTGCAGTATCC
NPVicR908 NP 888–908 GGGTCTATTCCCACCAAGGAA
NPVicP861 NP 861–878 FAM-TGGGTACGACTTCGAAAA-BHQ1
PAVicF1280 PA 1280–1299 AAATTGGAGAGGACGTAGCC
PAVicR1360 PA 1341–1360 TACAATGGGACACCTCTGCT
PAVicP1300 PA 1300–1323 FAM-CCAATTGAGCACATTGCAAGCATG-BHQ1
PB1VicF659 PB1 659–679 GAGCTTTGACATTGAACACGA
PB1VicR731 PB1 712–731 GGTGTTGCAATAGCCCTTCT
PB1VicP704r PB1 680–704 FAM-TTGCCTCTCTCTGCATCTTTGGTCA-BHQ1
PB2VicF999 PB2 999–1017 AAGCGGGTCATCAGTCAAA
PB2VicR1076 PB2 1052–1076 CCCTCATGTACTCTTATTCTCAATG
PB2-VicP1050r PB2 1024–1050 FAM-TTGGAGATTGCCTGTAAGCACCTCTTC-BHQ1
a
F and R in the primer name indicate forward and reverse direction, respectively. P indicates probe, and r indicates probe in reverse direction.













Shcherbik et al. Page 16
Table 3
Primers and probes used for real-time RT-PCR amplification of B/Texas/06/2011.
Primers/probesa Gene Nucleotides Sequence 5′ →3′
HATex_F226 HA 226–245 ACAGATCTGGATGTGGCCTT
HATex_R287 HA 267–287 GCTTTAGCAGAAGGTGTGGTC
HATex_P266r HA 247–266 FAM-CCCACACACATTGGCCTGCC-BHQ1
NATex_F718 NA 718–737 ATAACTGATGGCCCAGCTTC
NATex_R837 NA 817–837 GCATGTGCATTCCTCAGTATG
NATex_P779r NA 753–779 FAM-CGGCCTTCTCGAATCTTAAGGAATCTG-BHQ1
MTex_F256 M 256–275 ATGGGAACAACAGCAACAAA
MTex_R358 M 339–358 CATGGCCTTCTGCTATTTCA
MTex_P304r M 282–304 FAM-TTCTCTCAGCCAGAATCAGGCCC-BHQ1
NSTex_F377 NS 377–396 GGAGGTGCCTTGATGACATA
NSTex_R461 NS 438–461 TCTTTGTTGTTCATGTCCCTTAAT
NSTex_P426r NS 403–426 FAM-TGGGCCATCAACATCATCTGGTTC-BHQ1
NPTex_F159 NP 159–179 AGCAACCACAAGCAGTGAAGA
NPTex_R298 NP 279–298 TGAGTCCAGCTTTGACCATC
NPTex_P263r NP 243–263 FAM-TCGCCCAGTTTCACCACCATG-BHQ1
PATex_F260 PA 260–279 TAGCATGGATGGTCCAAAGA
PATex_R338 PA 316–338 TAATCAAACAAATCAGCCAGATA
PATex_P314r PA 288–314 FAM-TTGGGAGTCTCTATCCCATGCTCTTGA-BHQ1
PB1Tex_F141 PB1 141–166 TGAGTACTCGAACAAAGGAAAACAGT
PB1Tex_R215 PB1 194–215 GGCCCATTTGTTGGATCTATCA
PB1TexP168 PB1 168–187 FAM-TGTTTCTGACATCACAGGAT-BHQ1
PB2Tex_F587 PB2 587–607 AAGGAACGATGATAACTCCCA
PB2Tex_R657 PB2 637–657 GAACCTTCTCCTGGCAACTAA
PB2Tex_P636r PB2 614–636 FAM-TTCCCTCTCGAGCATGTATGCCA-BHQ1
a
F and R in the primer name indicate forward and reverse direction, respectively. P indicates probe, and r indicates probe in reverse direction.
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Table 4
Detection limits of each rRT-PCR assay.
Virus strain Primers/probe
Limit of detection 
(EID50/rxna)
Virus strain Primers/probe
Limit of detection (EID50/
rxn)
A/Victoria/361/2011 PB2V 0.08 B/Texas/06/2011 PB2T 0.1
PB1V 0.8 PB1T 0.1
PAV 0.8 PAT 0.1
NPV 0.8 NPT 1
MV 0.8 MT 1
NSV 0.8 NST 0.1
MDV-A H2 1.3 MDV-B HAU 1
NAL 1.3 NAU 1
a
rxn, rRT-PCR reaction containing 5 μl of RNA.
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Table 5





A/Leningrad/134/17/57 (MDV-A) wt A/Victoria/361/2011 B/USSR/60/69 (MDV-B) wt B/Texas/06/2011
PB2 22.23 No Cta 22.81 No Ct
PB1 21.45 No Ct 23.08 No Ct
PA 21.14 No Ct 22.35 No Ct
NP 22.27 No Ct 22.91 No Ct
M 22.39 No Ct 20.73 No Ct
NS 21.31 No Ct 23.11 No Ct
HA No Ct 22.89 No Ct 22.07
NA No Ct 21.76 No Ct 20.46
a
No signal was detected after 40 cycles of amplification.
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